Cimetidine suppression of nocturnal gastric secretion in active duodenal ulcer
- PMID: 2870
- DOI: 10.1056/NEJM197604082941502
Cimetidine suppression of nocturnal gastric secretion in active duodenal ulcer
Abstract
Nocturnal pain and gastric hypersecretion are common in duodenal ulcer. Therefore, we investigated the antisecretory effects of a new H2-receptor antagonist, cimetidine, in 200-, 300- or 400-mg doses, taken orally at bedtime. The 200-mg dose did not cause a statistically significant change in nocturnal (midnight to 7 a.m.) acid output and had only a borderline effect on pH. However, the 300-mg and 400-mg doses significantly (P less than 0.001) lowered acid output and increased (P less than 0.01) intragastric pH. All doses caused substantial decreases in secretory volume output. After a 400-mg dose, half the patients remained anacidic for eight hours. Dose-related increases of drug blood levels were observed and correlated with the degree and duration of inhibition of acid output. Serum gastrin levels were unaffected. Cimetidine appears to be a potent inhibitor of nocturnal gastric secretion.
Similar articles
-
Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer.N Engl J Med. 1975 Aug 21;293(8):371-5. doi: 10.1056/NEJM197508212930802. N Engl J Med. 1975. PMID: 239346 Clinical Trial.
-
The effect of cimetidine, a new histamine H2-receptor antagonist, on meal-stimulated acid secretion, serum gastrin, and gastric emptying in patients with duodenal ulcer.Gastroenterology. 1976 Jul;71(1):19-23. Gastroenterology. 1976. PMID: 6359 Clinical Trial.
-
Proceedings: Inhibition of nocturnal acid secretion in duodenal ulcer by oral metiamide.Gut. 1974 Apr;15(4):337. Gut. 1974. PMID: 4151865 Clinical Trial. No abstract available.
-
Postprandial gastric, pancreatic, and biliary response to histamine H2-receptor antagonists active duodenal ulcer.Gastroenterology. 1977 Jan;72(1):9-13. Gastroenterology. 1977. PMID: 11148 Clinical Trial.
-
Clinical effects of trithiozine, a newer gastric anti-secretory agent.J Int Med Res. 1979;7(5):452-8. doi: 10.1177/030006057900700521. J Int Med Res. 1979. PMID: 387498 Review.
Cited by
-
Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease.Drugs. 1978 Feb;15(2):93-131. doi: 10.2165/00003495-197815020-00002. Drugs. 1978. PMID: 342231 Review.
-
Controlled trial of cimetidine in reflux esophagitis.Dig Dis Sci. 1980 Oct;25(10):750-5. doi: 10.1007/BF01345293. Dig Dis Sci. 1980. PMID: 7000475 Clinical Trial.
-
Misoprostol, a synthetic PGE1 analog, in the treatment of duodenal ulcers. A multicenter double-blind study.Dig Dis Sci. 1985 Nov;30(11 Suppl):147S-158S. doi: 10.1007/BF01309402. Dig Dis Sci. 1985. PMID: 3932048 Clinical Trial.
-
Omeprazole inhibition of nocturnal gastric secretion in patients with duodenal ulcer.Br J Clin Pharmacol. 1984 Oct;18(4):587-90. doi: 10.1111/j.1365-2125.1984.tb02508.x. Br J Clin Pharmacol. 1984. PMID: 6487498 Free PMC article. Clinical Trial.
-
Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.Clin Pharmacokinet. 1991 Mar;20(3):218-36. doi: 10.2165/00003088-199120030-00004. Clin Pharmacokinet. 1991. PMID: 1673880 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources